Artificial intelligence: Artificial intelligence could help scientists make major advances against diseases such as cancer, Alzheimer’s, heart disease and mental health disorders within the next decade, Anthropic CEO Dario Amodei has predicted.
Speaking in an investor presentation released on November 10, Amodei said he believed these conditions could become “relics of the past” in less than 10 years through advances in AI and biological research.
He argued that increasingly capable AI systems could accelerate scientific discoveries, improve understanding of complex diseases and help researchers develop new medicines.
Amodei is not alone in highlighting AI’s medical potential. Google DeepMind CEO Demis Hassabis has also discussed how artificial intelligence could significantly shorten drug discovery timelines.
Google’s AlphaFold technology, for example, has predicted the structures of more than 200 million proteins, giving researchers access to valuable information for studying biological processes and developing potential treatments.
Medical experts urge caution
Despite the optimism, researchers and pharmaceutical industry figures have questioned whether the ambitious timelines are achievable.
Medical experts point out that identifying a promising drug candidate is only the beginning of a lengthy development process. Potential treatments must undergo laboratory experiments, preclinical testing and multiple phases of human clinical trials before receiving regulatory approval.
A typical drug development programme can take 10 to 15 years, although AI tools may help accelerate certain stages, including identifying disease targets and screening potential drug compounds.
Research published in 2026 shows that AI-designed drug candidates have advanced into human clinical trials, but no fully AI-discovered and AI-designed drug has yet received marketing approval.
Some industry leaders have also questioned whether current AI systems can independently deliver effective medicines without extensive human research and experimental testing.
Anthropic expands into medical research
Anthropic has been increasing its involvement in biological research and drug discovery, exploring how its AI technology could assist scientists in developing new treatments.
The company has expanded its work in biotechnology through acquisitions and research initiatives, including laboratory facilities focused on biological science.
While AI is already helping researchers analyse complex data and explore potential drug candidates, scientists say its ability to produce approved treatments for major diseases remains unproven.
Amodei’s prediction has therefore renewed debate about whether rapid advances in artificial intelligence could significantly change medicine over the coming decade.
